论文部分内容阅读
目的研究凋亡抑制蛋白Survivin和Livin在非小细胞肺癌(NSCLC)细胞核中阳性表达(核阳)水平及其临床意义。方法采用免疫组织化学SP法检测40例NSCLC组织和20例癌旁正常肺组织中Survivin蛋白和Livin蛋白核阳水平,并分析其与临床特征的关系。结果在NSCLC和癌旁正常肺组织中,Survivin蛋白细胞核表达的阳性率分别为80%(32/40)和5%(1/20),Livin蛋白细胞核表达的阳性率分别为80%(32/40)和10%(2/20)。Survivin蛋白和Livin蛋白核阳在NSCLC组织中的表达显著高于癌旁组织(P<0.05)。Survivin蛋白核阳与淋巴结转移、肿瘤分期高度相关(P<0.05)。结论 Survivin蛋白和Livin蛋白在NSCLC细胞核中高表达,可能成为NSCLC诊断的新指标和治疗的潜在靶点。
Objective To investigate the expression of Survivin and Livin in the nuclei of non-small cell lung cancer (NSCLC) and its clinical significance. Methods Immunohistochemical SP method was used to detect Survivin protein and Livin protein nuclear positive levels in 40 NSCLC tissues and 20 adjacent normal lung tissues, and their relationship with clinical features was analyzed. Results The positive rates of Survivin protein in nucleus were 80% (32/40) and 5% (1/20) respectively in NSCLC and adjacent normal lung tissues, and the positive rates of Livin protein in nucleus were 80% (32 / 40) and 10% (2/20). Survivin protein and Livin protein nuclear positive expression in NSCLC tissue was significantly higher than the adjacent tissue (P <0.05). Survivin protein nuclear positive and lymph node metastasis, tumor stage highly correlated (P <0.05). Conclusion The high expression of Survivin protein and Livin protein in the nucleus of NSCLC may be a new target for the diagnosis of NSCLC and a potential therapeutic target.